Recent Advances in PROTACs for Drug Targeted Protein Research

Area of Science:

• Biochemistry
• Molecular Biology
• Drug Discovery

Background:

• Proteolysis-targeting chimera (PROTAC) is a heterobifunctional molecule.
• PROTACs facilitate targeted protein degradation via the ubiquitin-proteasome system (UPS).
• PROTACs bind target proteins and E3 ligases, forming a ternary complex for ubiquitination and subsequent proteasomal degradation.

Purpose of the Study:

• To review recent advancements in PROTAC technology.
• To summarize and prospect hot targets and indications for PROTACs.
• To highlight the potential of PROTACs in biomedical research and development.

Main Methods:

• Literature review of recent studies on PROTACs.
• Analysis of PROTAC applications in various disease fields.
• Identification of key targets and therapeutic indications.

Main Results:

• PROTACs have demonstrated efficacy in degrading various cancer and disease-related proteins.
• Successful examples include PROTACs targeting AR, BR, BTK, Tau, and IRAK4.
• PROTACs show significant clinical efficacy in oncology, neurodegenerative diseases, and inflammatory conditions.

Conclusions:

• PROTACs represent a rapidly developing area in drug discovery.
• They offer a promising new modality for treating a wide range of diseases.
• The field is poised for continued expansion and innovation.